RT Journal Article
T1 Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
A1 de Miguel Pérez, Diego
A1 Rodriguez Martínez, Alba
A1 Ortigosa Palomo, Alba
A1 Delgado Ureña, Mayte
A1 Garcia Puche, Jose Luis
A1 Robles Remacho, Agustín
A1 Exposito Hernandez, José
A1 Lorente Acosta, Jose Antonio
A1 Ortega Sánchez, Francisco Gabriel
A1 Serrano, Ma Jose
K1 Extracellular vesicles
K1 Colorectal neoplasms
K1 Chemotherapy
K1 Bevacizumab
K1 MicroRNAs
K1 Vesículas extracelulares
K1 Neoplasias colorrectales
K1 Quimioterapia
K1 MicroARNs
AB Disseminated disease is present in ≈50% of colorectal cancer patients upon diagnosis, being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab, to chemotherapy, has increased progression free survival and overall survival of metastatic colorectal cancer (mCRC) patients. However, these benefits have been only reported in a small proportion of patients. To date, there are not biomarkers that could explain the heterogeneity of this disease and would help in treatment selection. Recent findings demonstrated that microRNAs (miRNAs) play an important role in cancer and they can be encapsulated with high stability into extracellular vesicles (EVs) that are released in biological fluids. EVs can act as cell-to-cell communicators, transferring genetic information, such as miRNAs. In this context, we aimed to investigate serum EV associated miRNAs (EV-miRNAs) as novel non-invasive biomarkers for the diagnosis and prognosis of Bevacizumab-treated mCRC patients. We observed that baseline miRNA-21 and 92a outperformed carcinoembryonic antigen levels in the diagnosis of our 44 mCRC patients, compared to 17 healthy volunteers. In addition, patients who died presented higher levels of miRNA-92a and 222 at 24 weeks. However, in the multivariate Cox analysis, higher levels of miRNA-222 at 24 weeks were associated with lower overall survival. Altogether, these data indicate that EV-miRNAs have a strong potential as liquid biopsy biomarkers for the identification and prognosis of mCRC.
PB Springer Nature
YR 2020
FD 2020-03-04
LK http://hdl.handle.net/10668/4273
UL http://hdl.handle.net/10668/4273
LA en
NO De Miguel Pérez D, Rodriguez Martínez A, Ortigosa Palomo A, Delgado Ureña M, Garcia Puche JL, Robles Remacho A, et al. Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients. Sci Rep. 2020 Mar 4;10(1):3974
DS RISalud
RD Apr 17, 2025